Transdermal Patch for Valentonin and 6-Methoxyharmalan
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sleep disorders, insomnia, and neurodegenerative diseases like Parkinson's and Alzheimer's fail to effectively regulate the body's sleep-wake system, leading to inadequate sleep and cognitive issues due to imbalances in valentonin (VLT) and 6-methoxy-harmalan (6-MH) levels.
Innovation Solution
A transdermal therapeutic system containing a combination of valentonin and 6-methoxy-harmalan, administered via adhesive patches, to replicate the natural secretion profile of these hormones, ensuring balanced levels and regulating the sleep-wake system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for sleep disorders are used, then sleep issues are addressed, but they fail to effectively regulate the sleep-wake system and cause imbalances in VLT and 6-MH levels
Solution Approach 1:
The invention changes the chemical parameters by introducing a specific combination of valentonin and 6-methoxy-harmalan in defined ratios (1:4 to 1:10) to restore natural hormone balance. This directly addresses the hormone level imbalances caused by current treatments while maintaining effective sleep regulation.
Solution Approach 2:
The transdermal patch serves as an intermediary delivery system that gradually introduces VLT and 6-MH into the bloodstream, avoiding the harsh effects of oral administration and achieving平稳 hormone level regulation without the harmful imbalances associated with current medications.
2Duration of action of moving object
If transdermal delivery is used, then sustained release and natural secretion mimicry are achieved, but device complexity increases
Solution Approach 1:
The transdermal patch is designed to release hormones in periodic cycles that mimic the natural circadian rhythm of melatonin secretion, with higher VLT release during nighttime (sleep phase) and higher 6-MH release during daytime (wake phase). This periodic delivery achieves sustained natural-like hormone levels while using a relatively simple patch structure.
3Reliability
If valentonin and 6-methoxy-harmalan are administered in correct ratios, then sleep-wake system regulation is improved, but manufacturing precision requirements increase
Solution Approach 1:
The invention combines valentonin and 6-methoxy-harmalan into a single transdermal patch formulation with pre-determined ratios (1:4 to 1:10). This merging of two hormones into one delivery system simplifies manufacturing compared to separate administrations while ensuring precise ratio control for effective sleep-wake regulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system provides sustained release of VLT and 6-MH, mimicking natural hormone secretion, thereby promoting restorative sleep, reducing insomnia, and potentially halting the progression of neurodegenerative diseases by maintaining a harmonious sleep-wake cycle.
Implementation Method 1
adhesive transdermal therapeutic system containing as active ingredient a combination of valentonin (VLT) and 6-methoxy-harmalan (6-MH)
Data Source
AI summary
The invention relates to an adhesive transdermal therapeutic system containing, as an active principle, an association of valentonin (VLT) and 6-methoxyharmalan (6-MH).